Citigroup resumed coverage on Owens & Minor with a new price target
$OMI
Medical Specialities
Health Care
Citigroup resumed coverage of Owens & Minor with a rating of Buy and set a new price target of $55.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/19/2024 | $24.00 → $19.00 | Neutral → Buy | Citigroup |
| 2/26/2024 | $24.00 | Market Perform | Leerink Partners |
| 1/3/2024 | $21.00 | Equal Weight | Barclays |
| 10/13/2022 | $52.00 → $18.00 | Buy → Neutral | Citigroup |
| 10/12/2022 | $43.00 → $17.00 | Buy → Underperform | BofA Securities |
| 10/12/2022 | $62.00 → $22.00 | Outperform → Neutral | Robert W. Baird |
| 4/26/2022 | $55.00 | Buy | Citigroup |
| 4/1/2022 | $43.00 | Neutral | Credit Suisse |
10-K - OWENS & MINOR INC/VA/ (0000075252) (Filer)
8-K - OWENS & MINOR INC/VA/ (0000075252) (Filer)
8-K - OWENS & MINOR INC/VA/ (0000075252) (Filer)
Gomez assumes leadership of Owens & Minor's people strategy with a focus on cultivating talent that supports company performance Owens & Minor, Inc. (NYSE:OMI), a leading global healthcare solutions company, today announced the appointment of Tammy Gomez as Executive Vice President & Chief Human Resources Officer, effective July 11, 2022. Gomez will report to Owens & Minor's President and Chief Executive Officer, Edward A. Pesicka, and be a member of the company's executive leadership team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220622005306/en/Owens & Minor names Tammy Gomez EVP and Chief Human Resources Officer, effect
Total Debt Reduction of $244 Million in 2024, Capping a Two-Year Total Debt Reduction of $647 Million 2025 Guidance Midpoint Indicates Double-Digit Adjusted EBITDA & Adjusted EPS Growth, and Improving Cash Flow Active Discussions Well Underway Regarding Potential Sale of Products & Healthcare Services (P&HS) Segment Board of Directors Authorizes Share Repurchase Program of Up to $100 Million Owens & Minor, Inc. (NYSE:OMI) today reported financial results for the fourth quarter and year ended December 31, 2024. "We are pleased with the progress that we have made against the strategy as outlined at our Investor Day in December 2023. As a reminder, we committed to optimizing our Prod
Expects to Report Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025 Owens & Minor, Inc. (NYSE:OMI) (the "Company") today announced selected preliminary financial results for the fourth quarter and year ended December 31, 2024 in advance of its upcoming earnings announcement and conference call. The release of the preliminary results relates to the Company's commencement of financing activity related to its previously announced agreement to acquire Rotech Healthcare Holdings, Inc ("Rotech"). "We are commencing a process to raise additional debt while the capital markets are attractive, to finance our previously announced agreement to acquire Rotech which we continu
Top-Line Growth Driven by Continued Solid Demand in Patient Direct and Medical Distribution Total Debt Reduction of Nearly $200 Million in the Third Quarter Owens & Minor, Inc. (NYSE:OMI) today reported financial results for the third quarter ended September 30, 2024. Key Highlights: Consolidated revenue of $2.7 billion in the third quarter, representing year-over-year growth of 5% GAAP Net loss of $(13) million or $(0.17) per share, and adjusted earnings per share of $0.42 in the third quarter Adjusted EBITDA of $142 million in the third quarter, representing year-over-year growth of 5% $198 million in total debt reduction in the third quarter "Our third quarter results demons
4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)
4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)
4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)
Citigroup upgraded Owens & Minor from Neutral to Buy and set a new price target of $19.00 from $24.00 previously
Leerink Partners initiated coverage of Owens & Minor with a rating of Market Perform and set a new price target of $24.00
Barclays initiated coverage of Owens & Minor with a rating of Equal Weight and set a new price target of $21.00
Total Debt Reduction of $244 Million in 2024, Capping a Two-Year Total Debt Reduction of $647 Million 2025 Guidance Midpoint Indicates Double-Digit Adjusted EBITDA & Adjusted EPS Growth, and Improving Cash Flow Active Discussions Well Underway Regarding Potential Sale of Products & Healthcare Services (P&HS) Segment Board of Directors Authorizes Share Repurchase Program of Up to $100 Million Owens & Minor, Inc. (NYSE:OMI) today reported financial results for the fourth quarter and year ended December 31, 2024. "We are pleased with the progress that we have made against the strategy as outlined at our Investor Day in December 2023. As a reminder, we committed to optimizing our Prod
Now available as a free service exclusively to Byram Healthcare customers, ByramConnect powered by the Welldoc App combines digital health coaching, self-tracking, clinically relevant insights and education to support members with diabetes and associated chronic health conditions throughout their health journey. Byram Healthcare, a leader in home-based care and part of the Owens & Minor (NYSE:OMI) family, recently launched ByramConnectTM, a personalized digital health program powered by the Welldoc App®. Using the Welldoc App's advanced artificial intelligence capabilities, the program analyzes member data across six dimensions of health to help optimize outcomes for people with type 1 or
Expects to Report Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025 Owens & Minor, Inc. (NYSE:OMI) (the "Company") today announced selected preliminary financial results for the fourth quarter and year ended December 31, 2024 in advance of its upcoming earnings announcement and conference call. The release of the preliminary results relates to the Company's commencement of financing activity related to its previously announced agreement to acquire Rotech Healthcare Holdings, Inc ("Rotech"). "We are commencing a process to raise additional debt while the capital markets are attractive, to finance our previously announced agreement to acquire Rotech which we continu
SC 13G/A - OWENS & MINOR INC/VA/ (0000075252) (Subject)
SC 13G/A - OWENS & MINOR INC/VA/ (0000075252) (Subject)
SC 13G/A - OWENS & MINOR INC/VA/ (0000075252) (Subject)
4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)